3 August 2023Big PharmaMarisa Woutersen

BMS and AstraZeneca settle dispute for $510m

Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

18 January 2022 The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.

More on this story

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

More on this story

Americas

BMS loses UK appeal over blood-thinning drug

9 May 2023 Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.

Americas

Bristol Myers can’t convince circuit to overturn $1.2bn ruling